论文部分内容阅读
Objective To observe the effect and safety of lobaplatin combinated floxuridine/pirarubicin in transcatheter hepatic arterial chemoembolization(TACE) of unresectable primary liver cancer. Methods TACE combinated with the lobaplatinbased chemotherapy regimen was used to treat 34 unresectable primary liver cancer patients. The DSA/MRI/CT/blood routine examinations were used to evaluate the short term activity and toxicity after 4-5 weeks, the process was repeated if necessary. The results were observed. Results Among the 34 cases, 1 case(2.9%) showed a complete response, 21 cases(61.7%) showed a partial response, 8 cases(23.5%) showed stable disease, and 4 cases showed progressive disease, with a total effective rate of 67.6%. The content of AFP dropped by over 50% in 20 cases(58.8%). The rate of recovery was hepatalgia(88.2%),ascites(47.1%),appetite(55.9%), Performance Status(30.4%). The median follow-up time(MFT)was 281day(s63-558 days),The median pro-gression-free survival was 118.5 days(95%,CI:88.8-148.2days). Adverse reaction(sIIIIV grade)were less commom, Only 4 cases of vomiting and 2 cases of thrombocytopenia(III grade) were observed. Conclusion Lobaplatin-based TACE is an effective and safe treatment for primary liver cancer.
Objective To observe the effect and safety of lobaplatin combinated floxuridine / pirarubicin in transcatheter hepatic arterial chemoembolization (TACE) of unresectable primary liver cancer. Methods TACE combinated with the lobaplatinbased chemotherapy regimen was used to treat 34 unresectable primary liver cancer patients. The DSA / MRI Results of the 34 cases, 1 case (2.9%) showed a complete response , Showed a partial response, 8 cases (23.5%) showed stable disease, and 4 cases showed progressive disease, with a total effective rate of 67.6%. The content of AFP dropped by over 50% in 20 cases (58.8%). The rate of recovery was hepatalgia (88.2%), ascites (47.1%), appetite (55.9%), Performance Status (30.4%). The median follow-up time (MFT) was 281day (s63-558 days), The median pro-gression-free survival was 118.5 d Atypical (95% CI: 88.8-148.2 days). Adverse reaction (sIIIIV grade) were less commom, only 4 cases of vomiting and 2 cases of thrombocytopenia (III grade) were observed. Conclusion Lobaplatin-based TACE is an effective and safe treatment for primary liver cancer.